Anti-infective Agents Market Worth $144.8 Billion By 2026

The global anti-infective agents market size is expected to reach over USD 144.8 billion by 2026 according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.4% during the forecast period. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongst people regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/anti-infective-agents-market

Further key findings from the report suggest:

Antiviral was estimated to be the largest segment with a market share of 48.8% in 2018 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
Antibacterial segment is anticipated to register the fastest CAGR of 4.0% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
Oral route of administration was estimated to be the largest segment in 2018 owing to new product development and presence of strong product pipeline
Hospital pharmacy led the anti-infective agents market in 2018 while e-commerce is expected to be the fastest growing segment during the forecast period
North America was one of the leading regions in terms of revenue in 2018. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
Some of the major companies operating in this market are Abbott; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim; and Novartis AG.
Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Lactoferrin Market Size Worth $379.5 Million By 2027

The global lactoferrin market size is projected to reach USD 379.5 million by 2027, registering a revenue-based CAGR of 8.1% over the forecast period, according to a new report published by Grand View Research, Inc. Increasing incorporation of lactoferrin in various products ranges including infant food, food supplements, dietetic foods, alcoholic beverages, sports nutrition, and personal care and cosmetics should bolster lactoferrin market in the forecast timeframe, ascribed to strong health benefits.

Lactoferrin offers stimulating effects on immune system, prevents cell damage caused by aging, promotes culture of beneficial bacterial in the intestinal tract, and regulates viruses, bacteria and fungi along with being regulator to iron metabolism. Lactoferrin is found effective for the treatment of hepatitis C infection by inhibiting replication of the virus at intracellular level. Hence, strong applicability of lactoferrin in nutraceutical, pharmaceutical, and personal care industries is anticipated to drive demand during the forecast period.

Human colostrum has the highest lactoferrin concentration, followed by human milk and then by bovine milk. It is also readily found in human body secretions including nose, eyes, intestine, and respiratory tract. Lactoferrin can be used as a conjuncture of specific strains of friendly bacteria, together they are proven to boost immune function of the body, alert the white blood cells of the harmful microbes, and to stabilize colonies of gut friendly bacteria. Commercially, lactoferrin is commonly integrated with probiotics to achieve this.

Asia Pacific is expected to expand at a CAGR of over 7.5% during the forecast period. The lactoferrin market is projected to witness strong rise in demand, as the key market players continue adopting strategies to expand its presence in untapped economies of South East Asia. Countries including China, Japan, and Australia have experienced high awareness regarding the health benefits of lactoferrin, which is expected to bolster regional growth over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/lactoferrin-market

Further key findings from the report suggest:

In terms of functions offered by lactoferrin, iron absorption segment accounted for the largest market share of over 29.0% in terms of revenue in 2019. This growth is expected to be supported by the growing incidences of iron deficiency and related disorders like anemia
Lactoferrin helps in restricting growth of acne due to its antioxidant properties. It helps combat free radicals formed due to natural process of oxidation. These free radicals can damage the cells and tissues promoting inflammation and acne. Such factors are expected to drive the product demand in personal care and cosmetics
Increasing investment in research, new product development, expansion of operation in developing nations, partnerships and collaboration with local players, and acquisition of small and medium sized players are among the major operational strategies taken up by key participants to strengthen and sustain their market positions

Veterinary Anti-infectives Market Size Worth $8.5 Billion By 2026

The global veterinary anti-infectives market size is anticipated to reach at USD 8.5 billion by 2026, registering a 6.4% CAGR during the forecast period, according to a new report published by Grand View Research, Inc. Rising prevalence of zoonotic diseases and bacterial infection, such as bovine TB, anthrax, and animal flu, is the key market driver. These diseases possess higher threat not only to animals but also to humans as they are food-borne, vector-borne, and communicable by direct and indirect contact. As per the Centers for Disease Control and Prevention (CDC) 2018, salmonella was the most common bacteria affecting the humans, especially the vets. The incidence and mortality rate might approach 100% during salmonella outbreaks. Antibiotics are used as an effective treatment for such outbreaks. This factor is anticipated to drive the market in near future.

Pharma giants are heavily investing in veterinary health R&D to not only address the growing disease burden but also to provide a better veterinary healthcare system. For instance, Zoetis increased their R&D fund from USD 382 million in 2017 to USD 432 million in 2018. Boehringer Ingelheim also invested around USD 41.90 million in 2018 for establishing new R&D facilities and for expanding their existing plants. The company also initiated 400 more clinical trials globally.

Groundbreaking technological advancements are rapidly transforming the veterinary anti-infectives market and are producing lucrative potentials for key participants. Some of the major market players are Merck & Co. Inc.; Zoetis; Boehringer Ingelheim; Ceva Santé Animale; Virbac; and others which account for a substantial market share, owing to their extensive product portfolio. Adoption of big data in livestock farming and wearable technologies to monitor pet health, are some of the notable strategic initiatives adopted by the market players.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/veterinary-anti-infectives-market

Further key findings from the study suggest:

Livestock held the dominant market share in 2018, due to important socio-cultural and economic roles of livestock, such as income and employment source, food supply, livelihood, agricultural diversification and sustainable agriculture
Antibacterial segment held the largest market share in 2018, due to rising consumption of antibacterial drugs to curb the outbreaks of zoonotic diseases, globally
Oral route of administration is the most preferred method and the segment held the dominant market share in 2018, due to the ease and comfort of administration through this method
E-commerce segment is anticipated to witness rewarding CAGR over the forecast period due to convenience provided to pet and livestock owners reluctant to purchase medicines from retail or hospital pharmacies
Zoetis, Vetiquinol, Merck, Boehringer Ingelheim GmbH, and Ceva Santé Animale are some of the major market participants due to their extensive product offerings and regional presence
Companies are adopting different strategies, such as new product development, partnerships, mergers and acquisitions, strategic collaborations, and regional penetration to gain competitive advantage